| General Information | |
|---|---|
| ZINC ID | ZINC000095576678 |
| Molecular Weight (Da) | 447 |
| SMILES | Cn1cc(C(=O)N[C@@H]2C(C)(C)[C@H]3CC[C@]2(C)C3)c(=O)c2ccc(Sc3ccccc3)cc21 |
| Molecular Formula | C27N2O2S1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.365 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 32 |
| LogP | 5.912 |
| Activity (Ki) in nM | 1862.09 |
| Polar Surface Area (PSA) | 76.4 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.06814324 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 16 |
| Fraction csp3 | 0.41 |
| Ilogp | 4.46 |
| Xlogp3 | 6.22 |
| Wlogp | 5.63 |
| Mlogp | 4.35 |
| Silicos-it log p | 5.41 |
| Consensus log p | 5.22 |
| Esol log s | -6.57 |
| Esol solubility (mg/ml) | 0.000121 |
| Esol solubility (mol/l) | 0.00000027 |
| Esol class | Poorly sol |
| Ali log s | -7.61 |
| Ali solubility (mg/ml) | 0.000011 |
| Ali solubility (mol/l) | 2.45E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.29 |
| Silicos-it solubility (mg/ml) | 0.00000227 |
| Silicos-it solubility (mol/l) | 5.09E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.61 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.89 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.121 |
| Logd | 4.388 |
| Logp | 6.173 |
| F (20%) | 0.659 |
| F (30%) | 0.442 |
| Mdck | - |
| Ppb | 95.03% |
| Vdss | 0.967 |
| Fu | 3.73% |
| Cyp1a2-inh | 0.235 |
| Cyp1a2-sub | 0.633 |
| Cyp2c19-inh | 0.789 |
| Cyp2c19-sub | 0.512 |
| Cl | 2.752 |
| T12 | 0.018 |
| H-ht | 0.24 |
| Dili | 0.745 |
| Roa | 0.045 |
| Fdamdd | 0.967 |
| Skinsen | 0.219 |
| Ec | 0.003 |
| Ei | 0.022 |
| Respiratory | 0.913 |
| Bcf | 2.348 |
| Igc50 | 5.145 |
| Lc50 | 5.27 |
| Lc50dm | 6.595 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.011 |
| Nr-ahr | 0.028 |
| Nr-aromatase | 0.7 |
| Nr-er | 0.498 |
| Nr-er-lbd | 0.02 |
| Nr-ppar-gamma | 0.676 |
| Sr-are | 0.547 |
| Sr-atad5 | 0.016 |
| Sr-hse | 0.38 |
| Sr-mmp | 0.854 |
| Sr-p53 | 0.547 |
| Vol | 467.121 |
| Dense | 0.955 |
| Flex | 0.185 |
| Nstereo | 3 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.565 |
| Synth | 4.337 |
| Fsp3 | 0.407 |
| Mce-18 | 104.421 |
| Natural product-likeness | -0.079 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |